Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryGynecologic

500 enrolled

Breast Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05856630 2023-05-12

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Phase 1 Unknown

24 enrolled

Prostatic Neoplasms

NCT05633342 2023-03-20

CADENCE

BreastGastrointestinalGenitourinaryGynecologic

15,000 enrolled

Breast Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04768868 2023-02-24

WEE1

Phase 1 Unknown

350 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01972867 2023-02-01

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

6 enrolled

Neoplasms, Prostatic Neoplasms

NCT05700370 2023-01-26

MyProstateScore Equivalency With and Without DRE

800 enrolled

Neoplasms, Prostatic Neoplasms

NCT05227898 2022-10-25

RESTORE

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmThoracic

352 enrolled

Breast Neoplasms, Colonic Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT05572099 2022-10-07

ExoDx Prostate Evaluation in Active Surveillance Patient Population

750 enrolled

Prostatic Neoplasms

NCT03235687 2022-05-06

Decision Impact Trial of the ExoDx Prostate (IntelliScore)

1,000 enrolled

Prostatic Neoplasms

NCT05180305 2022-01-06

A Study to Assess Mitomic Prostate Test for Prostate Cancer Screening

200 enrolled

Prostatic Neoplasms

NCT04582656 2021-08-06

VIOLETTE

65 enrolled

Neoplasms, Prostatic Neoplasms

NCT04783636 2021-03-17

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

Phase 1 Unknown

40 enrolled

Prostatic Neoplasms

NCT03520478 2021-03-02

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 3 Unknown

654 enrolled

Prostatic Neoplasms

NCT03896958 2020-12-04

PIONEER

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

1,000 enrolled

Adenocarcinoma of Lung, Adrenal Gland Neoplasms, Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms, Unknown Primary, Neurologic Manifestations, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Uterine Neoplasms, Vulvar Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT04632251 2020-11-17

LPM-012

56 enrolled

Prostatic Neoplasms

NCT02691975 2020-05-13

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Phase 1/2 Unknown

197 enrolled

Prostatic Neoplasms

NCT04066335 2019-12-18

Study to Evaluate the Safety of Nanoxel M Inj.